The joint venture aims to address unmet needs in the treatment of mood and anxiety disorders through novel neuroplastogens.

In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior ...

Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how ...

In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Melissa Lattanzi, VP, Emerging Therapies, Cencora ...

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued ...

Study findings indicated that psilocybin can reduce the symptoms of depression, with response and remission rates showing ...

Respondents said they were concerned about their own mental health or the mental health of another person at higher rates ...

The National Institute for Public Employee Healthcare Policy attributed the importance to the rising cost of health care.

It’s long past time for the industry to fully embrace the digital age. It’s fine to keep paper back-ups of data, but using ...

The new care center will offer primary care services to uninsured and underinsured patients in the Wilmington, North Carolina ...

The FDA first approved Ozempic, Novo Nordisk’s GLP-1 receptor agonist to improve glycemic control in adults with type 2 ...

Myhibbin is reportedly the first FDA-approved liquid formulation of mycophenolate, a key immunosuppressant used to prevent ...